Download PDF
Horm Metab Res 2017; 49(02): 77-85
DOI: 10.1055/s-0042-121894
Review
© Georg Thieme Verlag KG Stuttgart · New York

A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours

A. Yordanova
1   Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
,
H. Ahmadzadehfar
1   Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
,
M. Gonzalez-Carmona
2   Department of Internal Medicine 1, University Hospital Bonn, Bonn, Germany
,
C. Strassburg
2   Department of Internal Medicine 1, University Hospital Bonn, Bonn, Germany
,
K. Mayer
3   Department of Internal Medicine 3, University Hospital Bonn, Bonn, Germany
,
G. Feldmann
3   Department of Internal Medicine 3, University Hospital Bonn, Bonn, Germany
,
I. Schmidt-Wolf
3   Department of Internal Medicine 3, University Hospital Bonn, Bonn, Germany
,
P. Lingohr
4   Department of Surgery, University Hospital Bonn, Bonn, Germany
,
S. Fischer
5   Department of Radiology, University Hospital Bonn, Bonn, Germany
,
G. Kristiansen
6   Department of Pathology, University Hospital Bonn, Bonn, Germany
,
M. Essler
1   Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany
› Author Affiliations
Further Information

Publication History

received 16 August 2016

accepted 15 November 2016

Publication Date:
18 January 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Neuroendocrine tumours (NET) are rare neoplasms, but the incidence is permanently increasing. Most of the NETs are slow proliferating and clinically silent, and for that reason, they are often diagnosed at a stage with advanced disease. The complexity and diversity of the NET-biology require the treatment of patients in specialised centres to guarantee a qualified, multidisciplinary treatment planning. At our institution, we developed an interdisciplinary model for the assessment and treatment of NET. The aim was to adapt the guidelines to the clinical practice, exchange of current knowledge, and a tailored approach to the individual patient. In our team are included medical professionals from pathology, radiology, oncology, gastroenterology, oncological surgery, and nuclear medicine. In this paper, we describe step-by-step a procedural algorithm for the management of patients with neuroendocrine tumours, focusing on midgut-NETs in terms of therapy.

Key words

neuroendocrine tumours - NET - midgut - clinical - management
 

  • References

  • 1 Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451 (Suppl. 01) S9-S27
    CrossrefPubMedGoogle Scholar
  • 2 Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011; 18 (Suppl. 01) S1-S16
    CrossrefPubMedGoogle Scholar
  • 3 Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec J, Wiedenmann B. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401
    CrossrefPubMedGoogle Scholar
  • 4 Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec J, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762
    CrossrefPubMedGoogle Scholar
  • 5 Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17: 909-918
    CrossrefPubMedGoogle Scholar
  • 6 Anlauf M. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification. Horm Metab Res 2011; 43: 825-831
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16: 885-894
    CrossrefPubMedGoogle Scholar
  • 8 Pape U, Böhmig M, Berndt Ut, Tiling N, Wiedenmann B, Plöckinger U. Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center. Annals of the New York Academy of Sciences 2004; 1014: 222-233
    CrossrefPubMedGoogle Scholar
  • 9 Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807-1843
    CrossrefPubMedGoogle Scholar
  • 10 Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, van Cutsem E, Tesselaar M, Shimada Y, Oh D, Strosberg J, Kulke MH, Pavel ME. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4). A randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968-977
    CrossrefPubMedGoogle Scholar
  • 11 Landerholm K, Falkmer S, Järhult J. Epidemiology of Small Bowel Carcinoids in a Defined Population. World J Surg 2010; 34: 1500-1505
    CrossrefPubMedGoogle Scholar
  • 12 Pape U, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wiedenmann B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15: 1083-1097
    CrossrefPubMedGoogle Scholar
  • 13 Helland SK, Prosch AM, Viste A. Carcinoid tumours in the gastrointestinal tract - A population-based study from Western Norway. Scand J Surg 2006; 95: 158-161
    CrossrefPubMedGoogle Scholar
  • 14 Niederle MB, Niederle B. Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Tumors: Current Data on a Prospectively Collected, Retrospectively Analyzed Clinical Multicenter Investigation. Oncologist 2011; 16: 602-613
    CrossrefPubMedGoogle Scholar
  • 15 Pape U, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2011; 95: 135-156
    PubMedGoogle Scholar
  • 16 Miederer M, Seidl S, Buck A, Scheidhauer K, Wester H, Schwaiger M, Perren A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 48-52
    CrossrefPubMedGoogle Scholar
  • 17 Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J, Mendez G, Roca E. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010; 42: 220-225
    CrossrefPubMedGoogle Scholar
  • 18 Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol A, Nilsson O, Scarpa A, Scoazec J, Wiedenmann B, Papotti M, Rindi G, Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 162-166
    CrossrefPubMedGoogle Scholar
  • 19 Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007; 15: 407-414
    CrossrefPubMedGoogle Scholar
  • 20 Saqi A, Alexis D, Remotti F, Bhagat G. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005; 123: 394-404
    CrossrefPubMedGoogle Scholar
  • 21 Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 2009; 33: 626-632
    CrossrefPubMedGoogle Scholar
  • 22 Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Kloppel G, Komminoth P, Perren A. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 2008; 32: 420-425
    CrossrefPubMedGoogle Scholar
  • 23 Grabowski P, Schrader J, Wagner J, Horsch D, Arnold R, Arnold CN, Georgieva I, Stein H, Zeitz M, Daniel PT, Sturm I. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2008; 14: 7378-7384
    CrossrefPubMedGoogle Scholar
  • 24 Besig S, Voland P, Baur DM, Perren A, Prinz C. Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids. Neuroendocrinology 2009; 90: 402-415
    CrossrefPubMedGoogle Scholar
  • 25 Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems. Pancreas 2010; 39: 707-712
    CrossrefPubMedGoogle Scholar
  • 26 Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
    CrossrefPubMedGoogle Scholar
  • 27 Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 07) 124-130
    Google Scholar
  • 28 Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152-160
    CrossrefPubMedGoogle Scholar
  • 29 Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G, Komminoth P, Solcia E. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO Classification of Tumours of the Digestive System, ed. 2010; 4: 13-14
    PubMedGoogle Scholar
  • 30 Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, Delle Fave G, Falconi M. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833
    CrossrefPubMedGoogle Scholar
  • 31 Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, Koch M, Röcken C, Rindi G, Ruszniewski P, Wiedenmann B, Pape U. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117: 3332-3341
    CrossrefPubMedGoogle Scholar
  • 32 Anlauf M, Gerlach P, Schott M, Raffel A, Krausch M, Knoefel WT, Pavel M, Kloppel G. Pathology of neuroendocrine neoplasms. Chirurg 2011; 82: 567-573
    CrossrefPubMedGoogle Scholar
  • 33 Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose K, Scherag A, Hahmann M, Muller H, Barth P. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-827
    CrossrefPubMedGoogle Scholar
  • 34 Korse CM, Bonfrer JMG, Aaronson NK, Hart AAM, Taal BG. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. Neuroendocrinology 2009; 89: 296-301
    CrossrefPubMedGoogle Scholar
  • 35 Kema IP, Meijer WG, Meiborg G, Ooms B, Willemse PH, de Vries EG. Profiling of Tryptophan-related Plasma Indoles in Patients with Carcinoid Tumors by Automated, On-Line, Solid-Phase Extraction and HPLC with Fluorescence Detection. Clin Chem 2001; 47: 1811-1820
    CrossrefPubMedGoogle Scholar
  • 36 Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG. Discriminating Capacity of Indole Markers in the Diagnosis of Carcinoid Tumors. Clin Chem 2000; 46: 1588-1596
    PubMedGoogle Scholar
  • 37 Ardill JES, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003; 10: 459-462
    CrossrefPubMedGoogle Scholar
  • 38 O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape U, Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202
    CrossrefPubMedGoogle Scholar
  • 39 Oberg K. Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment. Ann Oncol 1999; 10: S3-S8
    PubMedGoogle Scholar
  • 40 McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980; 79: 1324-1331
    CrossrefPubMedGoogle Scholar
  • 41 Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg 2006; 93: 264-275
    CrossrefPubMedGoogle Scholar
  • 42 Fahrenkrug J. Vasoactive Intestinal Polypeptide: Measurement, Distribution and Putative Neurotransmitter Function. Digestion 1979; 19: 149-169
    CrossrefPubMedGoogle Scholar
  • 43 Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The Glucagonoma Syndrome Clinical and Pathologic Features in 21 Patients. Medicine 1996; 75:
    PubMed
  • 44 Isgro MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015; 867: 125-143
    CrossrefPubMedGoogle Scholar
  • 45 Korse CM, Taal BG, Vincent A, van Velthuysen MF, Baas P. Buning-Kager Johanna CGM, Linders TC, Bonfrer JMG. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer 2012; 48: 662-671
    CrossrefPubMedGoogle Scholar
  • 46 van Adrichem RCS, Kamp K, Vandamme T, Peeters M, Feelders RA, Herder WW. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Ann Oncol 2016; 27: 746-747
    CrossrefPubMedGoogle Scholar
  • 47 Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Guggenberg E, von Bale R, Virgolini IJ. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT. J Nucl Med 2007; 48: 508-518
    CrossrefPubMedGoogle Scholar
  • 48 Haug A, Auernhammer CJ, Wangler B, Tiling R, Schmidt G, Goke B, Bartenstein P, Popperl G. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009; 36: 765-770
    CrossrefPubMedGoogle Scholar
  • 49 Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010; 91: 101-109
    CrossrefPubMedGoogle Scholar
  • 50 Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008; 112: 2447-2455
    CrossrefPubMedGoogle Scholar
  • 51 Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011; 52: 1864-1870
    CrossrefPubMedGoogle Scholar
  • 52 Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?. Clin Nucl Med 2014; 39: e27-e34
    CrossrefPubMedGoogle Scholar
  • 53 Partelli S, Rinzivillo M, Maurizi A, Panzuto F, Salgarello M, Polenta V, Delle Fave G, Falconi M. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology 2014; 100: 293-299
    CrossrefPubMedGoogle Scholar
  • 54 Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun 2016; 37: 874-881
    CrossrefPubMedGoogle Scholar
  • 55 Bailey AA, Debinski HS, Appleyard MN, Remedios ML, Hooper JE, Walsh AJ, Selby WS. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol 2006; 101: 2237-2243
    CrossrefPubMedGoogle Scholar
  • 56 van Tuyl SAC, van Noorden JT, Timmer R, Stolk MFJ, Kuipers EJ, Taal BG. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc 2006; 64: 66-72
    CrossrefPubMedGoogle Scholar
  • 57 Pape U, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plockinger U, Salazar R, Grossman A. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95: 135-156
    CrossrefPubMedGoogle Scholar
  • 58 Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176
    CrossrefPubMedGoogle Scholar
  • 59 Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol A, Nilsson O, Scarpa A, Scoazec J, Wiedenmann B, Papotti M. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2008; 90: 162-166
    PubMedGoogle Scholar
  • 60 Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'connor JM, Salazar R, Taal BG, Vullierme MP, O'Toole D. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2011; 95: 120-134
    PubMedGoogle Scholar
  • 61 Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec J, Salazar R, Sauvanet A, Kianmanesh R. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119
    CrossrefPubMedGoogle Scholar
  • 62 Niederle B, Pape U, Costa F, Gross D, Kelestimur F, Knigge U, Oberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O’Toole D, Krenning E, Reed N, Kianmanesh R. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103: 125-138
    CrossrefPubMedGoogle Scholar
  • 63 Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape U, Oberg K. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172-185
    CrossrefPubMedGoogle Scholar
  • 64 Lepage C, Bouvier A, Manfredi S, Dancourt V, Faivre J. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 2006; 101: 2826-2832
    CrossrefPubMedGoogle Scholar
  • 65 Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, Sevilla-Garcia I, Villabona-Artero C, Beguiristain-Gomez A, Llanos-Munoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jimenez-Fonseca P, Teule A, Sastre-Valera J, Benavent-Vinuelas M, Monleon A, Salazar R. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794-1803
    CrossrefPubMedGoogle Scholar
  • 66 Maggard MA, O'Connell JB, Ko CY. Updated Population-Based Review of Carcinoid Tumors. Ann Surg 2004; 240: 117-122
    CrossrefPubMedGoogle Scholar
  • 67 Han S. Surgically treated primary malignant tumor of small bowel. A clinical analysis. World J Gastroenterol 2010; 16: 1527
    CrossrefPubMedGoogle Scholar
  • 68 Evrard S, Becouarn Y, Fonck M, Brunet R, Mathoulin-Pelissier S, Picot V. Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination. Eur J Surg Oncol 2004; 30: 399-406
    CrossrefPubMedGoogle Scholar
  • 69 Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10: 1059-1069
    CrossrefPubMedGoogle Scholar
  • 70 Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, Johnston M, McCormack P, Pass H, Putnam JB. Long-term results of lung metastasectomy. Prognostic analyses based on 5206 cases. J Thor Cardiovasc Surg 1997; 113: 37-49
    CrossrefPubMedGoogle Scholar
  • 71 Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M. Pulmonary metastasectomy for 165 patients with colorectal carcinoma. A prognostic assessment. J Thor Cardiovasc Surg 2002; 124: 1007-1013
    CrossrefPubMedGoogle Scholar
  • 72 Kianmanesh R, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J. Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases. J Chir (Paris) 2005; 142: 208-219
    CrossrefPubMedGoogle Scholar
  • 73 Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver. J Am College Surg 2003; 197: 29-37
    CrossrefPubMedGoogle Scholar
  • 74 Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, Tiensuu Janson E, Akerstrom G. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26: 991-997
    CrossrefPubMedGoogle Scholar
  • 75 Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O, Janson ET, Hellman P, Akerstrom G. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012; 36: 1419-1431
    CrossrefPubMedGoogle Scholar
  • 76 Krausch M, Raffel A, Anlauf M, Schott M, Lehwald N, Krieg A, Topp SA, Cupisti K, Knoefel WT. “Cherry picking”, a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours. World J Surg 2014; 38: 392-401
    CrossrefPubMedGoogle Scholar
  • 77 Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M, Mayer C, Aminossadati B, Pape U, Blaker M, Harder J, Arnold C, Gress T, Arnold R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
    CrossrefPubMedGoogle Scholar
  • 78 Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663-666
    CrossrefPubMedGoogle Scholar
  • 79 Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233
    CrossrefPubMedGoogle Scholar
  • 80 Eriksson B, Kloppel G, Krenning E, Ahlman H, Plockinger U, Wiedenmann B, Arnold R, Auernhammer C, Korner M, Rindi G, Wildi S. Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8-19
    CrossrefPubMedGoogle Scholar
  • 81 Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188
    PubMedGoogle Scholar
  • 82 Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study. Oncologist 2014; 19: 930-936
    CrossrefPubMedGoogle Scholar
  • 83 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Mittra E, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results. J Nucl Med 2016; 57: 629
    PubMedGoogle Scholar
  • 84 Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 800-816
    CrossrefPubMedGoogle Scholar
  • 85 Baum RP, Kulkarni HR. Theranostics: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics 2012; 2: 437-447
    CrossrefPubMedGoogle Scholar
  • 86 Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog 177 Lu-DOTA 0,Tyr3octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130
    CrossrefPubMedGoogle Scholar
  • 87 Wong FC, Kim EE. Therapeutic Applications of Radiopharmaceuticals. In: Handbook of Nuclear Medicine and Molecular Imaging: Principles and Clinical Applications. Kim EE, Lee D-S, Tateishi U, Baum RP. (eds.). Singapore: World Scientific Publising Co.; 2012: 401
    CrossrefGoogle Scholar
  • 88 Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 2010; 21: 787-794
    CrossrefPubMedGoogle Scholar
  • 89 Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, Willinek W, Biersack H, Sabet A. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014; 41: 925-933
    CrossrefPubMedGoogle Scholar
  • 90 Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack H, Ezziddin S. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging 2015; 42: 1238-1246
    CrossrefPubMedGoogle Scholar
  • 91 van Essen M, Krenning EP, Kam BLR, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2010; 51: 383-390
    CrossrefPubMedGoogle Scholar
  • 92 Sabet A, Haslerud T, Pape U, Sabet A, Ahmadzadehfar H, Grunwald F, Guhlke S, Biersack H, Ezziddin S. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014; 41: 205-210
    CrossrefPubMedGoogle Scholar
  • 93 Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232
    CrossrefPubMedGoogle Scholar
  • 94 Olsen IH, Sorensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, Langer SW. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. Sci World J 2012; 2012: 170496
    PubMedGoogle Scholar
  • 95 Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen D, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275
    CrossrefPubMedGoogle Scholar
  • 96 Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda L, Bertetto O, Papotti M, Dogliotti L. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 2009; 9: 388
    CrossrefPubMedGoogle Scholar
  • 97 Bajetta E, Catena L, Procopio G, de Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol 2007; 59: 637-642
    CrossrefPubMedGoogle Scholar
  • 98 Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm 2012; 27: 561-569
    CrossrefPubMedGoogle Scholar
  • 99 Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. The Cochrane Library 2009
    PubMed
  • 100 Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, Biersack H, Ahmadzadehfar H. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med 2012; 53: 1663-1669
    CrossrefPubMedGoogle Scholar
  • 101 Ahmadzadehfar H, Biersack H, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40: 105-121
    CrossrefPubMedGoogle Scholar
  • 102 Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A. Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis. J Vasc Interv Radiol 2004; 15: 335-345
    CrossrefPubMedGoogle Scholar
  • 103 Ahmadzadehfar H, Meyer C, Ezziddin S, Sabet A, Hoff-Meyer A, Muckle M, Logvinski T, Schild HH, Biersack HJ, Wilhelm K. Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. Eur J Nucl Med Mol Imaging 2013; 40: 80-90
    CrossrefPubMedGoogle Scholar
  • 104 Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M, Ducreux M. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13: 136-140
    PubMedGoogle Scholar
  • 105 Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71: 2624-2630
    CrossrefPubMedGoogle Scholar
  • 106 Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502-1522
    PubMedGoogle Scholar
  • 107 McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002; 94: 3307-3312
    CrossrefPubMedGoogle Scholar
  • 108 Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317: 1699-1701
    CrossrefPubMedGoogle Scholar
  • 109 Carty FL, Shortt CP, Shelly MJ, O’Connell MJ, Eustace SJ. PET/CT, whole-body MRI, and whole-body CT in the diagnosis, staging, and follow-up of malignancy. Science 2015; 2: e27
    PubMedGoogle Scholar